Dyadic International, Inc.
140 Intracoastal Pointe Drive
Suite 404
Jupiter
Florida
33477
United States
Tel: 561-743-8333
Fax: 561-743-8343
Website: http://www.dyadic-group.com/
Email: memalfarb@dyadic-group.com
259 articles about Dyadic International, Inc.
-
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
9/26/2023
Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA ("mRNA").
-
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
9/19/2023
Dyadic International, Inc today announced that it entered into a development and exclusive license agreement to commercialize certain non-animal dairy enzymes used in the production of food products using Dapibus™.
-
Dyadic to Present at BioProcess International
9/12/2023
Dyadic International, Inc. today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.
-
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
8/9/2023
Dyadic International, Inc. announced its financial results for the second quarter of 2023, and highlighted recent company developments.
-
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
7/26/2023
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced that it will report its financial results for the second quarter 2023 and host a corporate update conference call on Wednesday, August 9, 2023.
-
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
7/24/2023
Dyadic International, Inc. today provided an update regarding its Phase 1 Clinical Trial for its DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate.
-
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
6/21/2023
Dyadic International, Inc. announced that it has entered into a Memorandum of Understanding with Essential Drugs Company Limited, the state owned pharmaceutical company under the Ministry of Health and Family Welfare of Bangladesh to facilitate biopharmaceutical research, pre-clinical development, cGMP production, clinical trials, regulatory and other relevant areas of interest in Bangladesh.
-
Dyadic to Participate at Upcoming Events in June 2023
6/1/2023
Dyadic International, Inc. announced that its management will be participating in the following events during the month of June.
-
Dyadic to Participate at Two Industry Events in May
5/10/2023
Dyadic International, Inc. today announced that they will be participating in the following events during the month of May.
-
Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
5/10/2023
Dyadic International, Inc. today announced its financial results for the first quarter of 2023, and highlighted recent company developments.
-
Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™
5/8/2023
Dyadic International, Inc. announced that it entered into a co-development and marketing agreement with Fermbox Bio Inc.
-
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
4/26/2023
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced that it will report its financial results for first quarter 2023 and host a corporate update conference call on Wednesday, May 10, 2023.
-
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
4/18/2023
Dyadic International, Inc. today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/640,483, titled "PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA" (the “Patent”), and is expected to provide patent protection through 2038.
-
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
4/12/2023
Dyadic International, Inc. announced it signed an expanded licensing agreement for its C1-cell protein expression platform with South Africa’s Rubic One Health to develop, manufacture, commercialize and distribute affordable vaccines and biologics for human and animal health in underserved African countries.
-
Dyadic to Present at World Vaccine Congress Washington 2023
3/30/2023
Dyadic International, Inc. announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccine Congress in Washington, D.C.
-
Dyadic Reports 2022 Year End Results and Recent Company Progress
3/29/2023
Dyadic International, Inc. announced its financial results for year end 2022 and highlighted recent Company progress.
-
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
3/15/2023
Dyadic International, Inc. today announced that it will report its financial results for the year ended 2022 and host a corporate update conference call on Wednesday, March 29, 2023.
-
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
3/7/2023
Dyadic International, Inc. today provided an update regarding its Phase 1 Clinical Trial for its DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate.
-
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
3/1/2023
Dyadic International, Inc. today announced that its management and business partners from VTT Technical Research Centre of Finland Ltd, will be participating at the following investor and industry events.
-
Dyadic to Participate in Two Upcoming Investor Conferences
2/2/2023
Dyadic International, Inc. today announced that its Chief Executive Officer, Mark Emalfarb will be participating in the following two upcoming conferences.